<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993680</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-NR. 2011-0358</org_study_id>
    <nct_id>NCT01993680</nct_id>
  </id_info>
  <brief_title>Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment</brief_title>
  <official_title>A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Baumann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disabling symptoms of blood pressure dysregulation, impaired swallowing and digestion are&#xD;
      common amongst Parkinson's patients. So far the exact pathophysiology for this is not fully&#xD;
      understood. There are results from pathological analyses that the autonomic nervous system is&#xD;
      also affected by the accumulation of alpha-Synuclein and that this might even happen in very&#xD;
      early stages of the disease process (Qualman et al., 1984; Wakabayashi et al., 1989;&#xD;
      Wakabayashi et al., 1990; Bloch et al., 2006).&#xD;
&#xD;
      Blood pressure dysregulation is a common autonomic symptom in Parkinson's patients and&#xD;
      treatment - currently most often achieved with Fludrocortisone - often leads to supine&#xD;
      hypertension (Plaschke et al., 1998; Braune et al., 1999; Magerkurth et al., 2005).&#xD;
&#xD;
      There are studies in patients with autonomic failure that indicate that Pyridostigmine&#xD;
      bromide might be an alternative treatment option without causing disabling supine&#xD;
      hypertension (Singer et al., 2003; Sandroni et al., 2005; Singer et al., 2006; Yamamoto et&#xD;
      al., 2006).&#xD;
&#xD;
      Delayed gastric emptying is also an autonomic symptom associated with Parkinson's disease. By&#xD;
      the elevation of the cholinergic tone with Pyridostigmine bromide the investigators also&#xD;
      expect to alleviate symptoms of delayed gastric emptying and obstipation, possibly even&#xD;
      facilitating the uptake of dopaminergic medication through the gut (Sadjadpour, 1983;&#xD;
      Bharucha et al., 2008).&#xD;
&#xD;
      Therefore the investigators designed a monocentric randomized, controlled, double blind,&#xD;
      crossover phase II trial to show non-inferiority of the effect of pyridostigmine bromide vs.&#xD;
      fludrocortisone on symptoms of autonomic dysregulation in Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In summary, investigators in recent years became more and more aware of the non-motor&#xD;
      symptoms of PD and their impact on affected individuals. Therefore therapeutic strategies to&#xD;
      ameliorate these symptoms are ever more needed. Sufficient clinical data for the treatment of&#xD;
      symptoms of blood pressure dysregulation is still lacking. This study is aiming at closing&#xD;
      this knowledge gap by comparing the efficacy and tolerability of a promising new agent,&#xD;
      pyridostigmine bromide with the standard treatment, fludrocortisone.&#xD;
&#xD;
      The proposed target of pyridostigmine in this respect is at the autonomic ganglion in the&#xD;
      efferent limb of the baroreflex. Via a reduction of acetylcholine breakdown the sympathetic&#xD;
      ganglionic transmission increases upon orthostatic stress (Singer et al., 2006).&#xD;
&#xD;
      Via the same mechanism we aim to facilitate gastrooesophageal motility and gastric emptying:&#xD;
      Both relaxation and contractibility of the oesophagus are known to be affected in PD patients&#xD;
      as shown in a manometric study (Sung et al., 2010). Both relaxation and contractability are&#xD;
      mainly influenced by nicotinergic and muscarinergic, cholinergic vagal efferents to the&#xD;
      oesophagus (Chang et al., 2003). Via a reduction of acetylcholine breakdown we aim to&#xD;
      increase the cholinergic tone and thereby normalize the reduced relaxation and&#xD;
      contractibility.&#xD;
&#xD;
      We also intent to show that this faster gastric transit results in a faster absorption of&#xD;
      Madopar into the bloodstream - we therefore will measure Levodopa and its metabolites during&#xD;
      the first 60mins after ingestion of 125mg fast-release Madopar in serial venous blood samples&#xD;
      via high-pressure liquid chromatography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 1, 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in diastolic blood pressure drop on Schellong manoeuvre</measure>
    <time_frame>10min standing, 10 min supine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in half emptying time t50 on 13C-sodium octanoate breath test</measure>
    <time_frame>within 4h after test meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Pyridostigmine bromide</measure>
    <time_frame>assess symptom severity for last 14 days</time_frame>
    <description>central blood pressure, heart rate variability and pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Pyridostigmine bromide</measure>
    <time_frame>assess symptom severity for last 14 days</time_frame>
    <description>Motor functions (UPDRS III), frequency and subjective quality of defecation, frequency and urgency of micturition, tremor severity (Whiget tremor scale);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; Tolerability of Pyridostigmine bromide</measure>
    <time_frame>assess symptom severity for last 14 days</time_frame>
    <description>subjective assessment of sialorrhea, Hospital Anxiety and Depression Scale, Montreal Cognitive Assessment;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Autonomic Disturbances in Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Pyridostigmine bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 days of active treatment followed by 21 days wash out</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fludrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days of fludrocortisone treatment; 21 days wash out</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine bromide</intervention_name>
    <description>Drug doses during the trial:&#xD;
Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days</description>
    <arm_group_label>Pyridostigmine bromide</arm_group_label>
    <other_name>Mestinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludrocortisone</intervention_name>
    <description>drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days</description>
    <arm_group_label>fludrocortisone</arm_group_label>
    <other_name>florinef</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  informed, written &amp; formal consent for participation&#xD;
&#xD;
          -  male / female subjects, aged 50-80 years&#xD;
&#xD;
          -  PD patients (18 subjects with symptomatic orthostatic hypotension)&#xD;
&#xD;
        Exclusion criteria: - Antihypertensive treatment&#xD;
&#xD;
          -  medication influencing gastrointestinal motility for at least the elimination half&#xD;
             life of the drug&#xD;
&#xD;
          -  medication interfering with blood-pressure regulation for at least the elimination&#xD;
             half life of the drug&#xD;
&#xD;
          -  significant systemic illness&#xD;
&#xD;
          -  BMI &lt;18 or &gt;30kg/m2&#xD;
&#xD;
          -  symptoms or a history of GI disease or surgery&#xD;
&#xD;
          -  with any evidence of infectious disease&#xD;
&#xD;
          -  evidence or history of drug or alcohol abuse&#xD;
&#xD;
          -  diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Baumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Neurology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol. 2006 Oct;23(5):476-81.</citation>
    <PMID>17016160</PMID>
  </reference>
  <reference>
    <citation>Sandroni P, Opfer-Gehrking TL, Singer W, Low PA. Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]--a follow-up survey study. Clin Auton Res. 2005 Feb;15(1):51-3.</citation>
    <PMID>15768203</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Christian Baumann</investigator_full_name>
    <investigator_title>Professor dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

